FDA Approves Journavx, New Nonopioid Med, for Acute Pain
Vertex Pharmaceuticals has received FDA approval for Journavx (suzetrigine), a non-opioid medication for moderate to severe acute pain in adults. This first-in-class drug targets the NaV1.8 pain-signaling receptor to prevent pain signals from reaching the brain, providing an alternative to opioids. With over 80 million Americans prescribed for acute pain annually, Journavx aims to reduce the risks associated with opioid use, including addiction. The approval is based on clinical trials showing significant pain reduction, and the drug is priced at $15.50 per 50 mg pill.
Managed Healthcare Executive